WT Wealth Management boosted its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 19.6% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 50,384 shares of the company’s stock after acquiring an additional 8,252 shares during the quarter. VanEck Pharmaceutical ETF comprises about 1.6% of WT Wealth Management’s portfolio, making the stock its 19th largest position. WT Wealth Management’s holdings in VanEck Pharmaceutical ETF were worth $5,234,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the company. AlphaCore Capital LLC acquired a new position in shares of VanEck Pharmaceutical ETF in the fourth quarter valued at about $31,000. Group One Trading LLC acquired a new stake in shares of VanEck Pharmaceutical ETF during the fourth quarter worth about $36,000. EFG International AG acquired a new stake in shares of VanEck Pharmaceutical ETF during the fourth quarter worth about $44,000. IFP Advisors Inc boosted its position in VanEck Pharmaceutical ETF by 53.7% in the third quarter. IFP Advisors Inc now owns 438 shares of the company’s stock valued at $40,000 after buying an additional 153 shares during the last quarter. Finally, Birchwood Financial Partners Inc. purchased a new stake in VanEck Pharmaceutical ETF in the fourth quarter valued at approximately $45,000.
VanEck Pharmaceutical ETF Trading Up 2.5%
Shares of NASDAQ:PPH opened at $109.44 on Friday. VanEck Pharmaceutical ETF has a twelve month low of $81.74 and a twelve month high of $112.58. The company has a market cap of $1.04 billion, a PE ratio of 20.21 and a beta of 0.47. The company’s 50 day moving average is $103.24 and its 200 day moving average is $104.61.
VanEck Pharmaceutical ETF Increases Dividend
VanEck Pharmaceutical ETF Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Featured Articles
- Five stocks we like better than VanEck Pharmaceutical ETF
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
